10 Best Dividend Paying Drug Manufacturing Stocks

Submitted by Dividend Yield as part of our contributors program.

The best dividend paying stocks from the major drug manufacturing industry originally published at “long-term-investments.blogspot.com“. The healthcare sector is another great investment field for me. I mainly like it because of the ongoing aging population. The older people are, the more healthcare they need. The big problem is that most of the people don’t have saved enough money to finance all their health services and products – The government must care for it and makes it via health care plans, insurance, hospitals, education and so on. This means also a state related dependence for the investor.

One of the best yielding industries within the healthcare sector is the major drug manufacturing industry. The average yield amounts to 3.85 percent and the P/E’s on a level of 18.0. The industry has exactly 10 dividend stocks and is still the biggest investment field followed by a ten times smaller Biotechnology industry. I believe that the bioteches will perform better and catch up to the leading industry unless the old drug companies will not overtake them. The reason is simple: They are more innovative.

However, below is a small list of the best dividend paying major drug manufacturing stocks. From 10 stocks have seven with a buy or even better rating. Despite the great predictions of decreasing sales and earnings due to patent losses, growth is still forecasted for the most of the drug dividend stocks.

Here are my favorite stocks:

GlaxoSmithKline (GSK) has a market capitalization of $108.42 billion. The company employs 97,389 people, generates revenue of $39.741 billion and has a net income of $7.133 billion. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $11.831 billion. The EBITDA margin is 29.77 percent (the operating margin is 27.97 percent and the net profit margin 17.95 percent).

Financial Analysis: The total debt represents 44.13 percent of the company’s assets and the total debt in relation to the equity amounts to 315.01 percent. Due to the financial situation, a return on equity of 65.96 percent was realized. Twelve trailing months earnings per share reached a value of $2.73. Last fiscal year, the company paid $2.23 in the form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 16.22, the P/S ratio is 2.74 and the P/B ratio is finally 12.41. The dividend yield amounts to 5.30 percent and the beta ratio has a value of 0.63.

Sanofi (SNY) has a market capitalization of $124.12 billion. The company employs 113,719 people, generates revenue of $45.771 billion and has a net income of $6.350 billion. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $13.360 billion. The EBITDA margin is 29.19 percent (the operating margin is 16.18 percent and the net profit margin 13.87 percent).

Financial Analysis: The total debt represents 15.41 percent of the company’s assets and the total debt in relation to the equity amounts to 27.46 percent. Due to the financial situation, a return on equity of 10.42 percent was realized. Twelve trailing months earnings per share reached a value of $2.95. Last fiscal year, the company paid $1.73 in the form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 15.94, the P/S ratio is 2.76 and the P/B ratio is finally 1.70. The dividend yield amounts to 3.94 percent and the beta ratio has a value of 0.90.

Bristol Myers Squibb (BMY) has a market capitalization of $60.83 billion. The company employs 28,000 people, generates revenue of $17.621 billion and has a net income of $2.501 billion. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $3.222 billion. The EBITDA margin is 18.28 percent (the operating margin is 13.28 percent and the net profit margin 14.19 percent).

Financial Analysis: The total debt represents 20.60 percent of the company’s assets and the total debt in relation to the equity amounts to 54.28 percent. Due to the financial situation, a return on equity of 13.25 percent was realized. Twelve trailing months earnings per share reached a value of $1.15. Last fiscal year, the company paid $1.37 in the form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 32.22, the P/S ratio is 3.45 and the P/B ratio is finally 4.45. The dividend yield amounts to 3.77 percent and the beta ratio has a value of 0.42.

Take a closer look at the full list of the best dividend paying drug stocks. The average P/E ratio amounts to 18.66 and forward P/E ratio is 13.35. The dividend yield has a value of 4.27 percent. Price to book ratio is 4.21 and price to sales ratio 2.84. The operating margin amounts to 20.82 percent and the beta ratio is 0.65. Stocks from the list have an average debt to equity ratio of 2.56.

Selected Articles:
· 20 Of The Best Yielding Healthcare Growth Stocks For The Next Years
· Most Recommended Healthcare Stocks For 2013
· My Best Healthcare Stock Picks For 2013
· 20 Of The Biggest Healthcare Dividend Payer

If you like to receive more news and regular dividend updates, you should subscribe to my free E-Mail list. Alternative, you can follow me on Facebook or Twitter.